| Overview |
| bs-9037R |
| PDZK3 Polyclonal Antibody |
| IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PDZK3 |
| 801-900/2839 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 23037 |
| Activated in prostate cancer protein; AIPC; KIAA0300; Likely ortholog of rat plakophilin related armadillo repeat protein interacting PDZ protein antibody PAPIN; PDZ domain containing 2; PDZ domain containing 3; PDZ domain containing protein 2; PDZ domain containing protein 3; PDZD2; PDZK 2; PDZK2; PDZK-2; PDZK 3; PDZK3; PDZK-3; PIN1; Plakophilin related armadillo repeat protein interacting PDZ protein like; Rat plakophilin related armadillo repeat protein interacting PDZ protein like; PDZD2_HUMAN. |
| Proteins containing PDZ domains have been shown frequently to bind the C-termini of transmembrane receptors or ion channels. They have also been shown to bind to other PDZ domain proteins and could possibly be involved in intracellular signalling. PDZK3 contains six PDZ domains and shares sequence similarity with pro-interleukin-16 (pro-IL-16). Like pro-IL-16, the encoded protein localizes to the endoplasmic reticulum and is thought to be cleaved by a caspase to produce a secreted peptide containing two PDZ domains. In addition, the PDZK3 gene is upregulated in primary prostate tumors and may be involved in the early stages of prostate tumorigenesis. |
| Application Dilution |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz